Vera Therapeutics Inc. Class A (VERA)
NASDAQ: VERAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
VERA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.84B
- EPS (TTM)
- -$5.90
- Dividend yield
- None
- 52-week range
- 25.08 – 56.05
- Day range
- 25.16 – 27.15
- Volume / Avg
- 1.37M / 1.95M
- Beta
- —
- Shares outstanding
- 72.30M
52-week range
VERA stock today
On Nov 20, VERA ended the session at $25.45, shedding $1.30 (4.86%), versus the S&P 500's 3.70% decline. At this level, VERA sits near the bottom of its 52-week range of $25.08 to $56.05: 54.6% below the high, set on Dec 24, 2025 and 1.5% above the low. VERA is down 49.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 10.6%.
Vera Therapeutics has posted a net loss over the last twelve months (EPS of -$5.90), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Vera Therapeutics
Company profileVera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Marshall W. Fordyce M.D.
- Headquarters
- Brisbane, CA
- Employees
- 362
- IPO year
- 2021
- Website
- veratx.com
Financial highlights
Full financialsVera Therapeutics reported a net loss of $299.6 million, compared with a loss of $152.1 million a year earlier. Diluted earnings per share came in at -$4.66.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-299.62M | $-152.15M | $-95.99M | $-89.06M | $-32.61M |
| EPS (diluted) | $-4.66 | $-2.75 | $-2.25 | $-3.35 | $-2.43 |
Analyst forecast
ForecastConsensus (14 analysts)
strong_buy
Avg. price target
$71.36+180.39%
- Strong buy 1
- Buy 11
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-1.26 vs $-1.72
- Surprise
- +26.74%
VERA news
All VERA news- Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Vera Therapeutics Reports Third Quarter 2026 Financial ResultsNasdaq
- Vera Therapeutics (VERA) Q3 2026 Earnings Call TranscriptNasdaq
- Vera Therapeutics GAAP EPS of -$1.30 beats by $0.32, revenue of $10.2M beats by $6.88MSeeking Alpha
- Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- Vera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation ConferenceGlobeNewswire
- Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of MedicineGlobeNewswire
- Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of...Business Insider
Vera Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SEPNSepterna Inc. | 38.61 | -1.51% | $1.84B | vs VERA |
| IMNMImmunome Inc. | 15.69 | -5.54% | $1.85B | vs VERA |
| MRVIMaravai LifeSciences Holdings Inc. Class A | 6.98 | -2.92% | $1.81B | vs VERA |
| BHVNBiohaven Ltd. | 12.39 | -9.23% | $1.87B | vs VERA |
| ZYMEZymeworks Inc. | 26.14 | -2.68% | $1.81B | vs VERA |
| TRVITrevi Therapeutics Inc. | 13.35 | -2.70% | $1.90B | vs VERA |
| HRMYHarmony Biosciences Holdings Inc. | 32.59 | -1.18% | $1.91B | vs VERA |
| ETONEton Pharmaceuticals Inc. | 60.85 | -0.83% | $1.76B | vs VERA |
Indexes, lists and sector
Vera Therapeutics stock FAQ
What is Vera Therapeutics's stock price today?
VERA last traded at $25.45 as of Nov 20, 4:00 PM EST, down 4.86% on the day. Prices are delayed at least 15 minutes.
Who is Vera Therapeutics's CEO?
Dr. Marshall W. Fordyce M.D. is the chief executive officer of Vera Therapeutics Inc. Class A, which has about 362 employees.
What is the VERA 52-week high?
The 52-week high for VERA is $56.05 and the 52-week low is $25.08. The stock is currently 54.6% below its high.